Endocrinologia
Em um estudo de coorte com seguimento mediano de 23,2 anos, níveis baixos e muito baixos de LDL-colesterol foram associados com risco aumentado de mortalidade cardiovascular na população geral.
5 Ago, 2022 | 17:35h
Estudo de coorte | Cirurgia bariátrica está associada a aumento no risco de casamentos ou divórcios.
5 Ago, 2022 | 17:28hComunicado de imprensa: Bariatric Surgery Linked to Doubling Chance of Marriage or Divorce – University of Pittsburgh
Estudo original: Changes in Marital Status Following Roux-en-Y Gastric Bypass and Sleeve Gastrectomy: A US Multicenter Prospective Cohort Study – Annals of Surgery Open
Comentário: Spouse Getting Weight Loss Surgery? Your Marriage Might Be in Trouble – HealthDay
M-A de rede | Resumo das evidências avaliando o ganho de peso corporal entre pessoas em terapia antirretroviral para tratamento de HIV.
5 Ago, 2022 | 17:06h
Comentário no Twitter
A new systematic review aimed to evaluate how different #ART regimens compare with respect to body #weight gains over time and associated risk factors.
Read here: https://t.co/MHC1Ysgb34 pic.twitter.com/0djjGPmlcW
— eClinicalMedicine – The Lancet Discovery Science (@eClinicalMed) May 24, 2022
Diretriz | Prevenção da obesidade em mulheres de meia-idade.
5 Ago, 2022 | 16:51hComunicado de imprensa: Women’s Preventive Services Initiative issues guidelines for preventing obesity in midlife women – American College of Physicians
Comentário: Counseling Can Prevent Obesity in Normal, Overweight Women – HealthDay
Comentário no Twitter
New guidelines aim to prevent #obesity in midlife women. @TheWPSI recommends counseling to prevent weight gain in all women at normal or overweight BMI. Full text available at https://t.co/P8VwBWIHXe @CedarsSinai @acog pic.twitter.com/YxTQVgXj59
— Annals of Int Med (@AnnalsofIM) August 2, 2022
Estudo mostra que a incidência de obesidade entre crianças nos EUA está aumentando.
5 Ago, 2022 | 16:23hChanges in the Incidence of Childhood Obesity – Pediatrics
Estudo original: Childhood Obesity Rate in the U.S. Higher Now Than 12 Years Prior – HealthDay
M-A | Agonistas receptores de GLP1 estão associados com risco aumentado de progressão de retinopatia em pacientes com diabetes tipo 2.
4 Ago, 2022 | 14:26hProgression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes – A systematic review and meta-analysis – Journal of Diabetes and its Complications (link para o resumo – $ para o texto completo)
Comentário: GLP1 RA use tied to increased risk of rapidly worsening retinopathy in type 2 diabetes – Medical Dialogues
Estudo randomizado | Segurança e eficácia da tirzepatida como adição à medicação anti-hiperglicêmia oral única em pacientes com diabetes tipo 2 no Japão.
4 Ago, 2022 | 14:09hSafety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial – The Lancet Diabetes & Endocrinology (link para o resumo – $ para o texto completo)
Ver também (nota: a dose de dulaglutida usada neste estudo foi provavelmente subótima): Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial – The Lancet Diabetes & Endocrinology (link para o resumo – $ para o texto completo)
Conteúdos relacionados:
Tirzepatide Once Weekly for the Treatment of Obesity – New England Journal of Medicine
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (link para o resumo – $ para o texto completo)
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentário no Twitter
Online—Safety and efficacy of #tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 #diabetes in #Japan (#SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial https://t.co/r4v4QUsl5q #T2D pic.twitter.com/k6ihWy2vem
— The Lancet Diabetes & Endocrinology (@TheLancetEndo) July 31, 2022
Estudo randomizado | Gastroplastia endoscópica para tratamento de obesidade classes 1 e 2.
2 Ago, 2022 | 13:28hEndoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial – The Lancet (link para o resumo – $ para o texto completo)
Comentário no Twitter
MERIT trial suggests endoscopic sleeve gastroplasty should be considered as a synergistic weight loss intervention for patients with class 1 or class 2 obesity.
Find out more: https://t.co/FWeXeWbBF0 pic.twitter.com/W6qUKW92hR
— The Lancet (@TheLancet) July 30, 2022
Estudo de coorte | Intensidade da atividade física nos momentos de lazer e mortalidade por todas as causas e por causas específicas.
2 Ago, 2022 | 13:22hLong-Term Leisure-Time Physical Activity Intensity and All-Cause and Cause-Specific Mortality: A Prospective Cohort of US Adults – Circulation (gratuito por tempo limitado)
Comunicado de imprensa: New study finds lowest risk of death was among adults who exercised 150-600 minutes/week – American Heart Association
Perspectiva | Aspirina para prevenção primária de doença cardiovascular aterosclerótica em mulheres.
2 Ago, 2022 | 13:20hAspirin for the Primary Prevention of Atherosclerotic Cardiovascular Disease in Women – JAMA (gratuito por tempo limitado)